Specialty Pharma Journal Specialty, Precision & Technology
AstraZeneca and MedImmune, its global biologics research and development arm, today announced final overall survival (OS) results for the Phase III MYSTIC trial, a randomised, open-label, multi-centre, global trial of Imfinzi (durvalumab) monotherapy and the combination of Imfinzi and tremelimumab, an anti-CTLA4 antibody, versus standard-of-care (SoC) platinum-based chemotherapy in previously-untreated patients with Stage IV …
Tag Archives: MedImmune
November, 2018
-
8 November
Immunomedics Expands Clinical Collaboration With Astrazeneca to Include Metastatic Non-Small Cell Lung Cancer
MORRIS PLAINS, N.J., Nov. 07, 2018 (GLOBE NEWSWIRE) — Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced its current clinical collaboration with AstraZeneca (NYSE: AZN) and MedImmune for the development of Imfinzi® (durvalumab) and sacituzumab govitecan combination therapy has been broadened to include second-line …
October, 2018
-
24 October
AstraZeneca Strengthens and Expands Oncology Development and Commercialization Collaboration with Innate Pharma
AstraZeneca, and its global biologics research and development arm MedImmune, today announced a new multi-term agreement with Innate Pharma (Innate), building on an existing collaboration, aimed at accelerating each company’s oncology portfolio and bringing new medicines to patients more quickly. The extended collaboration will enrich AstraZeneca’s immuno-oncology (IO) portfolio with …
September, 2018
-
25 September
Imfinzi is the First Immunotherapy to Demonstrate Significant Overall Survival Benefit in Unresectable, Stage III Lung Cancer
WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of IMFINZI® (durvalumab) during the Presidential Symposium of the IASLC 19th World Conference on Lung Cancer hosted by the International Association for the Study of Lung …
-
13 September
FDA Approves Lumoxiti for the Treatment of Certain Patients with Relapsed or Refractory Hairy Cell Leukemia
AstraZeneca and MedImmune, its global biologics research and development arm, announced today that the US Food and Drug Administration (FDA) has approved Lumoxiti (moxetumomab pasudotox-tdfk) for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a …
August, 2018
-
31 August
AstraZeneca’s Anifrolumab Fails to Meet the Primary Endpoint in its Phase 3 Trial in Systemic Lupus Erythematosus
AstraZeneca and MedImmune, its global biologics research and development arm, today announced top-line results from the TULIP 1 Phase III trial for anifrolumab in adult patients with moderate-to-severe systemic lupus erythematosus (SLE). The trial did not meet the primary endpoint of a statistically-significant reduction in disease activity in patients with SLE …
May, 2018
-
25 May
AstraZeneca’s Imfinzi Significantly Improves Overall Survival in Late-Stage Non-Small Cell Lung Cancer Study
WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca and MedImmune, its global biologics research and development arm, today announced positive overall survival (OS) results for the Phase III PACIFIC trial, a randomized, double-blinded, placebo-controlled, multi-center trial of IMFINZI® (durvalumab) in patients with unresectable Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following …
-
11 May
AstraZeneca’s Fasenra Fails in Late-Stage Chronic Obstructive Pulmonary Disease Trial
AstraZeneca and MedImmune, its global biologics research and development arm, today announced top-line results from the GALATHEA Phase III trial for Fasenra (benralizumab) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD). The trial did not meet the primary endpoint of a statistically-significant reduction of exacerbations in patients with …
April, 2018
-
5 April
FDA Accepts AstraZeneca’s Application for its Investigational Hairy Cell Leukemia Drug
Zene AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for moxetumomab pasudotox, an investigational anti-CD22 recombinant immunotoxin and a potential new medicine for the treatment of adult patients with hairy cell …
-
2 April
Compugen Enters Exclusive License Agreement with MedImmune for Bi-Specific and Multi-Specific Antibody Products
HOLON, Israel, April 2, 2018 /PRNewswire/ — Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced it entered into an exclusive license agreement with MedImmune, the global biologics research and development arm of AstraZeneca, to enable the development of bi-specific …